Fu Wen-yi
China
Research Article
Efficacy of Combination Therapy with rhTNFR:Fc and Methotrexate in the Patients with Disease-modifying Antirheumatic Drug -resistant Rheumatoid Arthritis
Author(s): Fu Wen-yi, Zhang Ning and Yang LiliFu Wen-yi, Zhang Ning and Yang Lili
Objective: To observe the efficacy of combining recombinant human tumour necrosis factor-Fc [rhTNFR:Fc ,etanercept] and methotrexate (MTX) in patients with disease-modifying antirheumatic drug (DMARD)-resistant rheumatoid arthritis.
Methods: Collected 64 active RA patients with DMARD-resistant, according to patients’ gender, age, duration and extent of disease activity, divided the 64 patients randomly into comparable two groups. The experimental group within thirty-two patients, were treated with twice-weekly subcutaneous etanercept (25 mg) and meanwhile weekly oral MTX (15 mg);the control group within thirty-two patients, were treated with daily oral prednisone (5-10 mg) and meanwhile weekly oral MTX (15 mg).Course of treatment is 12 weeks. Clinical response was assessed using American College of Rheumatology (ACR) criteria.
Result: As compared wi.. View More»
